

MEDICA SIGNS DEFINITIVE AGREEMENT WITH EVOQUA WATER TECHNOLOGIES TO ACQUIRE ASSETS TO MANUFACTURE BLOOD AND WATER FILTER PRODUCTS

Medolla (MO), 1 March 2023 - Medica S.p.A., an integrated Italian biomedical and MedTech group with a strong international footprint, announces that its subsidiary Medica USA Inc has entered into a definitive agreement with Evoqua Water Technologies (NYSE: AQUA), an industry leader in mission-critical water treatment solutions, to acquire assets to manufacture blood and water filter products. Evoqua will retain distribution rights to the water filter product line, including bioscience product filters and automated endoscope reprocessor (AER) filters.

The transaction is expected to close in the next 30-60 days.

The acquisition of these assets allows Medica to use its strong expertise in hollow fiber filter design and production to increase its portfolio products and continue bringing quality products to US and international markets, in line with the geographic expansion strategy of its business.

Upon closing of the transaction, Evoqua will enter into a supply agreement with Medica for bioscience product filters and automated endoscope reprocessor filters to continue serving its customers. These filters are typically used in pharmaceutical, medical, and industrial applications to maintain a high-quality filtration and disinfection environment.

Luciano Fecondini President and CEO of Medica USA and Medica SpA commented, *“This transaction represents a key step in the strategic growth of Medica USA as a manufacturer of blood and water filters and forecasts a long-term cooperation with Evoqua on water filter business based on the acquired technology.”*

About Evoqua Water Technologies

Evoqua Water Technologies is a leading provider of mission-critical water and wastewater treatment solutions, offering a broad portfolio of products, services, and expertise to support industrial, municipal, and recreational customers who value water. Evoqua has worked to protect water, the environment, and its employees for more than 100 years, earning a reputation for quality, safety, and reliability around the world. Headquartered in Pittsburgh, Pennsylvania, the company operates in more than 150 locations across nine countries. Serving more than 38,000 customers and 200,000 installations worldwide, our employees are united by a common purpose: Transforming Water. Enriching Life.® To learn more, visit www.evoqua.com.

Medica Profile

Medica Group is operating since 1985 in the biomedical district of Mirandola (Italy). Development of innovative products for blood purification has always been company's core business. Thanks to the activity of

two extremely dynamic R&D groups (medical equipment, membranes and disposable), the Group competes successfully in several markets, namely:

- **Medical** (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC, pre-transplant organ perfusion, bioregenerative medicine, gastroenterology, urodynamics, oxygen humidification).
- **Microbiological purification of water**
- **Industrial automation** for the biomedical sector.

R&D focus has been integrated over the years with a highly automated production systems in several facilities, and with different commercial entities, both in Italy and abroad.

The key success factors of the Group are:

- **extrusion of hollow fiber membranes** for hemofiltration, plasmapheresis, cascade filtration, oxygen humidification, ultrafiltration and microfiltration of water
- **vertical integration**, proved by the ability to manage not only the design and development of medical disposables and equipment, and the development of the automation technologies required for their production as well.
- **International recognition with significant share of export**, with sales in over 60 countries.

The Medica group closed its consolidated financial statements for 2021 with revenues of 43.8 million euros (44.1 million euros in 2020), EBITDA of 9.9 million euros (9.5 million euros in 2020), EBIT of € 5.8 million (€ 5.6 million in 2020) and net profit of € 5.0 million (€ 3.8 million in 2020).

For information:

Investor Relations Medica

Giovanni Plasmati

(+39) 0535 51159

giovanni.plasmati@medica.it

Euronext Growth Advisor

CFO SIM S.p.A.

(+39) 02 303431

ecm@cfosim.com